Evidence map›Paper›PMID 39121116›Full record

ArticleJournal of Alzheimer's disease : JAD2024

End-of-Life Healthcare Utilization in Lewy Body Dementia.

Golnoosh Alipour-Haris, Melissa J Armstrong, Amie J Goodin, Jingchuan Serena Guo, Joshua D Brown

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Golnoosh Alipour-HarisCenter of Drug Evaluation & Safety and Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL, USA.
Melissa J ArmstrongDepartments of Neurology and Health Outcomes & Biomedical Informatics, University of Florida College of Medicine, Gainesville, FL, USA.
Amie J GoodinCenter of Drug Evaluation & Safety and Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL, USA.
Jingchuan Serena GuoCenter of Drug Evaluation & Safety and Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL, USA.
Joshua D BrownCenter of Drug Evaluation & Safety and Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL, USA.

Funding

University of Florida - Mt. Sinai Medical Center AD Research CenterP50AG047266 · NIA · UNIVERSITY OF FLORIDA · PI FEBO, MARCELO · 2015 to 2019
$7.3M
Identifying Factors Predicting ACcurately End-of-Life in Dementia with Lewy Bodies and Promoting Quality End-of-Life Experiences: the PACE-DLB StudyR01AG068128 · NIA · UNIVERSITY OF FLORIDA · PI ARMSTRONG, MELISSA JO · 2020 to 2024
$3.4M
Smartphone phenotype collection for diagnostic screening of mild cognitive impairmentR44AG062072 · NIA · PARABON NANOLABS, INC. · PI ARMENTROUT, STEVEN L · 2021 to 2022
$1.9M
Higher Order Convolutional Neural Network for Classification of Lewy-body Diseases and Alzheimers DiseaseR01NS121099 · NINDS · UNIVERSITY OF FLORIDA · PI VEMURI, BABA C · 2024 to 2025
$735k
NIA NIH HHS P50 AG047266NIA NIH HHS R01 AG068128NIA NIH HHS R44 AG062072NINDS NIH HHS R01 NS121099
6 · The paper itself

Abstract

Background: Lewy body dementia (LBD) is the second most common neurodegenerative dementia in the US, presenting unique end-of-life challenges. Objective: This study examined healthcare utilization and care continuity in the last year of life in LBD. Methods: Medicare claims for enrollees with LBD, continuously enrolled in the year preceding death, were examined from 2011-2018. We assessed hospital stays, emergency department (ED) visits, intensive care unit (ICU) admissions, life-extending procedures, medications, and care continuity. Results: We identified 45,762 LBD decedents, predominantly female (51.8%), White (85.9%), with average age of 84.1 years (SD 7.5). There was a median of 2 ED visits (IQR 1-5) and 1 inpatient stay (IQR 0-2). Higher age was inversely associated with ICU stays (Odds Ratio [OR] 0.96; 95% Confidence Interval [CI] 0.96-0.97) and life-extending procedures (OR 0.96; 95% CI 0.95-0.96). Black and Hispanic patients experienced higher rates of ED visits, inpatient hospitalizations, ICU admissions, life-extending procedures, and in-hospital deaths relative to White patients. On average, 15 (7.5) medications were prescribed in the last year. Enhanced care continuity correlated with reduced hospital (OR 0.72; 95% CI 0.70-0.74) and ED visits (OR 0.71; 95% CI 0.69-0.87) and fewer life-extending procedures (OR 0.71; 95% CI 0.64-0.79). Conclusions: This study underscored the complex healthcare needs of people with LBD during their final year, which was influenced by age and race. Care continuity may reduce hospital and ED visits and life-extending procedures.

Indexed as

Lewy Body DiseaseMedicarePatient Acceptance of Health CareTerminal CareAgedAged, 80 and overContinuity of Patient CareEmergency Service, HospitalFemaleHospitalizationHumansIntensive Care UnitsMaleUnited StatesAlzheimer’s diseasecare continuitydementiademographicsend-of-life carehealthcare outcomesICU admissionsinpatient visitsLewy body diseaselife-extending proceduresmedication utilization

Identifiers

PMID39121116
PMCPMC11371273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.